|
 Kyprolis when used with two standard of care drugs, dexamethasone
and Celgene Corp's Revlimid, reduced the risk of death by 21 percent
and extended survival by 7.9 months, compared with patients treated
with the two drugs alone, the company said.
The study, ASPIRE, tested Kyprolis, chemically known as carfilzomib,
in multiple myeloma patients whose cancer had relapsed following
prior treatment or did not respond to treatment.
"The data support the early use of carfilzomib as an effective
therapy at first relapse, regardless of prior treatment with Velcade
or transplant," Keith Stewart, principal investigator on the study
said, referring to Takeda Pharmaceutical Co's cancer treatment.
Amgen said it had filed with the U.S. FDA requesting to include the
new overall survival data in the drug's label.
Kyprolis is approved for multiple myeloma that has progressed after
treatment with other medicines.
[to top of second column] |
In the United States, nearly 95,000 people are living with, or in
remission from, multiple myeloma, according to the National Cancer
Institute.
About 30,330 Americans are diagnosed with multiple myeloma and more
than 12,600 die from the disease each year.
(Reporting by Tamara Mathias in Bengaluru; Editing by Sriraj
Kalluvila)
[© 2017 Thomson Reuters. All rights
reserved.] Copyright 2017 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
 |
